ments.
Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other.
These notes are effectively junior to borrowings under our credit and security facility, to the extent if directly borrowed by our subsidiaries, and to liabilities of our subsidiaries (see Other Arrangements below).
Our senior notes consist of the following as of December 31, 2015:
## Table 0 ##
Our $4.050 billion of senior notes issued in 2009, 2013 and 2015 contain a change-in-control provision, which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal, plus accrued and unpaid interest, if a rating event, as defined in the indenture, occurs as a result of a change-in-control, as defined in the indenture.
Any other credit rating changes may impact our borrowing cost, but do not require us to repay any borrowings.
The interest rate payable on our November 2035 Notes is currently 7.00 percent.
Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3.
The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
Other Arrangements We also maintaina$300 million credit and security facility secured by our U. S.  trade receivables maturing on June 9, 2017.
The credit and security facility requires that we maintain a maximum leverage covenant consistent with the 2015 Facility.
The maximum leverage ratio requirement is 4.5 times and our actual leverage ratio as of December 31, 2015 is 3.0 times.
We had no borrowings outstanding under this facility as of December 31, 2015 and December 31, 2014.
We have accounts receivable factoring programs in certain European countries that we account for as sales under ASC Topic 860, Transfers and Servicing.
These agreements provide for the sale of accounts receivable to third parties, without recourse, of up to approximately $392 million as of December 31, 2015.
We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy.
We de-recognized $151 million of receivables as of December 31, 2015 at an average interest rate of 2.4 percent, and $167 million as of December 31, 2014 at an average interest rate of 3.2 percent.
In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for borrowings, promissory notes discounting and receivables factoring of up to 21.0 billion Japanese yen (approximately $175 million as of December 31, 2015).
We de-recognized $132 million of notes receivable as of December 31, 2015 at an average interest rate of 1.6 percent and $134 million of notes receivable as of December 31, 2014 at an average interest rate of 1.8 percent.
De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying consolidated balance sheets.
As of December 31, 2015, we had outstanding letters of credit of $44 million, as compared to $59 million as of December 31, 2014, which consisted primarily of bank guarantees and collateral for workers’ compensation insurance arrangements.
As of December 31, 2015 and 2014, none of the beneficiaries had drawn upon the letters of credit or guarantees; accordingly, we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of December 31, 2015 or 2014.
We believe we will generate sufficient cash from operations to fund these payments and intend to fund these payments without drawing on the letters of credit.
Financing Activities Our cash flows from financing activities reflect issuances and repayments of debt, proceeds from stock issuances related to our equity incentive programs and repurchases of common stock pursuant to our authorized repurchase programs, discussed in Note L—Stockholders’ Equity to our consolidated financial statements included in Item 8 of this Annual Report.
Additionally, our financing activities included $156 million of contingent payments in 2015, $34 million of payments in 2014 and $160 million of payments in 2013 associated with our previous acquisitions.
Our liquidity plans are subject to a number of risks and uncertainties, including those described in Item 1A.
Risk Factors of this Annual Report, some of which are outside our control.
Macroeconomic conditions, adverse litigation outcomes and other risk and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans.
Debt We had total debt of $5.677 billion as of December 31, 2015 and $4.244 billion as of December 31, 2014 which consisted of the following: Credit Facilities In April 2015, we entered into a new $2.000 billion revolving credit facility (the 2015 Facility) with a global syndicate of commercial banks and terminated our previous $2.000 billion revolving credit facility.
The 2015 Facility matures in April 2020.
There were no amounts borrowed under our current or prior revolving credit facility as of December 31, 2015 or December 31, 2014.
We also maintaina$300 million credit and security facility secured by our U. S.  trade receivables maturing on June 9, 2017.
We had no borrowings outstanding under this facility as of December 31, 2015 and December 31, 2014.
Term Loans In April 2015, we entered into a $750 million, unsecured term loan facility (2015 Term Loan).
We had $750 million outstanding under the 2015 Term Loan as of December 31, 2015.
In August 2013, we entered into a $400 million, unsecured term loan facility (2013 Term Loan).
We had $250 million outstanding under the 2013 Term Loan as of December 31, 2015 and $400 million outstanding as of December 31, 2014.
Our revolving credit facility and our term loan facilities require that we maintain certain financial covenants as outlined in Note F— Borrowings and Credit Agreements to our consolidated financial statements contained in Item 8 of this Annual Report.
As of and through December 31, 2015, we were in compliance with the required covenants.
Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs.
Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers.
Senior Notes We had $4.650 billion of senior notes outstanding as of December 31, 2015 and $3.800 billion outstanding as of December 31, 2014.
Our senior notes are publicly registered securities, are redeemable prior to maturity and are not subject to any sinking fund requirements.
Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other.
These notes are effectively junior to borrowings under our credit and security facility, to the extent if directly borrowed by our subsidiaries and liabilities of our subsidiaries.
The debt maturity schedule for the significant components of our debt obligations as of December 31, 2015 is as follows:
## Table 1 ##
Note: The table above does not include unamortized discounts associated with our senior notes, or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes or debt issuance costs.
Other Arrangements We have accounts receivable factoring programs in certain European countries that we account for as sales under ASC Topic 860, Transfers and Servicing.
These agreements provide for the sale of accounts receivable to third parties, without recourse, of up to approximately $392 million as of December 31, 2015.
We de-recognized $151 million of receivables as of December 31, 2015 at an average interest rate of 2.4 percent, and $167 million as of December 31, 2014 at an average interest rate of 3.2 percent.
In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for borrowings, promis- sory notes discounting and receivables factoring of up to 21.000 billion Japanese yen (approximately $175 million as of
American Medical Systems’ Portfolio.
This investment was subsequently repaid in the fourth quarter of 2015.
Xlumena, Inc.  On April 2, 2015, we acquired Xlumena, Inc.  (Xlumena), a medical device company that developed minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract.
The purchase agreement called for an upfront payment of $63 million, an addi- tional payment of $13 million upon FDA clearance of the HOT AXIOS?
product, and further sales-based milestones based on sales achieved through 2018.
We are in the process of integrating Xlumena into our Endoscopy business, and expect the integration to be substantially complete by the end of 2016.
In addition, we completed other acquisitions during 2015 for total consideration of $6 million in cash at closing plus contingent consideration of up to $1 million.
Purchase Price Allocation We accounted for these acquisitions as business combinations and, in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification?
(ASC) Topic 805, Business Combinations, we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates.
The components of the aggregate preliminary purchase prices are as follows (in millions):
## Table 2 ##
The following summarizes the aggregate preliminary purchase price allocation for the 2015 acquisitions as of December 31, 2015 (in millions):
## Table 3 ##
We allocated a portion of the preliminary purchase price to specific intangible asset categories as follows:
## Table 4 ##
2014 Acquisitions Interventional Business of Bayer AG On August 29, 2014, we completed the acquisition of the Interventional Division of Bayer AG (Bayer), for a total cash consideration of $414 million.
We believe that this acquisition enhances our ability to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions.
The transaction includes the AngioJet?
Thrombectomy System and the Fetch?2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream?
Atherectomy System, used to remove plaque and thrombi from diseased arteries.
We are integrating the operations of the Bayer business with our Peripheral Interventions and Interventional Cardiology divisions and expect integration to be substantially completed by the middle of 2016.
IoGyn, Inc.  On May 7, 2014, we completed the acquisition of the remaining fully diluted equity of IoGyn, Inc.  (IoGyn).
Prior to the acquisition, we held a 28 percent minority interest in IoGyn in addition to notes receivable of approximately $8 million.
Total consideration was comprised of a net cash payment of $65 million at closing to acquire the remaining 72 percent of IoGyn equity and repay outstanding debt.
IoGyn has developed the Symphion?
System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps.
In March 2014, IoGyn received U. S.  Food & Drug Administration (FDA) approval for the system and in October 2014, we began a limited market
intangible assets are impaired.
If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with ASC Topic 350, Intangibles-Goodwill and Other.
The following represents our goodwill balance by global reportable segment:
## Table 5 ##
*In 2014, we reallocated $7 million of goodwill between Cardiovascular and MedSurg as a result of the realignment of certain product lines from Endoscopy to Peripheral Interventions as of January 1, 2014.
The 2015 and 2014 purchase price adjustments relate primarily to adjustments in taxes payable and deferred income taxes, including changes in the liability for unrecognized tax benefits.2015 Goodwill Impairment Testing We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In the second quarter of 2015, we performed our annual goodwill impairment test for all of our reporting units, in accordance with ASC Topic 350, Intangibles-Goodwill and Other.
In conjunction with our annual test, the fair value of each reporting unit exceeded its carrying value.
Therefore, it was deemed not neces- sary to proceed to the second step of the impairment test.
As a result of the 2015 annual goodwill impairment test, we identified our global Electrophysiology reporting unit as being at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods.
As of the date of our annual goodwill impairment test, our global Electrophysiology reporting unit had excess fair value over carrying value of approximately 28 percent and held $292 million of allocated goodwill.
Also, as of the date of our annual goodwill impairment test, our global Cardiac Rhythm Management (CRM) reporting unit had excess fair value over carrying value of approximately 26 percent; however, due to goodwill impairment charges in prior years, no goodwill remains within our CRM reporting unit.
On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill.
The key variables that drive the cash flows of our reporting units are estimated revenue growth rates and levels of profitability.
Terminal value growth rate assumptions, as well as the WACC, are additional key variables for reporting unit cash flows.
These assumptions are subject to uncertainty, including our ability to grow revenue and improve profitability levels.
Relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant goodwill impairment charges.
For example, as of the date of our annual goodwill impairment test, keeping all other variables constant, a combined increase of 50 basis points in the WACC along with a simultaneous decrease of 150 basis points in the long term growth rate applied would require that we perform the second step of the goodwill impairment test for our global Electrophysiology reporting unit.
The estimates used for our future cash flows and discount rates represent management’s best estimates, which we believe to be reasonable, but future declines in business performance may result in impairment of our goodwill.
Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to: ‰ decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, pricing pressures, reductions in reimbursement levels, product actions, and/or competitive technology developments; ‰ declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies, product actions, and market and/or regulatory conditions that may cause sig- nificant launch delays or product recalls; ‰ decreases in our forecasted profitability due to an inability to successfully implement and achieve timely and sustainable cost improvement measures consistent with our expectations; ‰ negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products; ‰ the level of success of on-going and future research and development efforts, including those related to recent acquis

<table><tr><td></td><td>Amount(in millions)</td><td>IssuanceDate</td><td>Maturity Date</td><td>Semi-annualCoupon Rate</td></tr><tr><td>January 2017 Notes</td><td>$250</td><td>November 2004</td><td>January 2017</td><td>5.125%</td></tr><tr><td>October 2018 Notes</td><td>600</td><td>August 2013</td><td>October 2018</td><td>2.650%</td></tr><tr><td>January 2020 Notes</td><td>850</td><td>December 2009</td><td>January 2020</td><td>6.000%</td></tr><tr><td>May 2020 Notes</td><td>600</td><td>May 2015</td><td>May 2020</td><td>2.850%</td></tr><tr><td>May 2022 Notes</td><td>500</td><td>May 2015</td><td>May 2022</td><td>3.375%</td></tr><tr><td>May 2025 Notes</td><td>750</td><td>May 2015</td><td>May 2025</td><td>3.850%</td></tr><tr><td>October 2023 Notes</td><td>450</td><td>August 2013</td><td>October 2023</td><td>4.125%</td></tr><tr><td>November 2035 Notes</td><td>350</td><td>November 2005</td><td>November 2035</td><td>6.250%</td></tr><tr><td>January 2040 Notes</td><td>300</td><td>December 2009</td><td>January 2040</td><td>7.375%</td></tr><tr><td></td><td>$4,650</td><td></td><td></td><td></td></tr></table>
<table><tr><td>(in millions)</td><td>2016</td><td>2017</td><td>2018</td><td>2019</td><td>2020</td><td>Thereafter</td><td>Total</td></tr><tr><td>Senior Notes</td><td>$—</td><td>$250</td><td>$600</td><td>$—</td><td>$1,450</td><td>$2,350</td><td>$4,650</td></tr><tr><td>Term Loans</td><td>—</td><td>85</td><td>390</td><td>150</td><td>375</td><td>—</td><td>1,000</td></tr><tr><td></td><td>$—</td><td>$335</td><td>$990</td><td>$150</td><td>$1,825</td><td>$2,350</td><td>$5,650</td></tr></table>
<table><tr><td>Cash, net of cash acquired</td><td>$1,734</td></tr><tr><td>Fair value of contingent consideration</td><td>63</td></tr><tr><td></td><td>$1,797</td></tr></table>
<table><tr><td>Goodwill</td><td>$573</td></tr><tr><td>Amortizable intangible assets</td><td>1,073</td></tr><tr><td>Indefinite-lived intangible assets</td><td>7</td></tr><tr><td>Inventory</td><td>103</td></tr><tr><td>Property, Plant and Equipment</td><td>43</td></tr><tr><td>Other net assets</td><td>43</td></tr><tr><td>Deferred income taxes</td><td>-45</td></tr><tr><td></td><td>$1,797</td></tr></table>
<table><tr><td></td><td>AmountAssigned(in millions)</td><td>WeightedAverageAmortizationPeriod(in years)</td><td>Range of Risk-Adjusted DiscountRates used inPurchase PriceAllocation</td></tr><tr><td>Amortizable intangible assets:</td><td></td><td></td><td></td></tr><tr><td>Technology-related</td><td>$431</td><td>11-13</td><td>13.5% - 23%</td></tr><tr><td>Customer relationships</td><td>624</td><td>12-13</td><td>13.5% - 15%</td></tr><tr><td>Other intangible assets</td><td>18</td><td>13</td><td>13.5%</td></tr><tr><td>Indefinite-lived intangible assets:</td><td></td><td></td><td></td></tr><tr><td>In-process research & development</td><td>$7</td><td>N/A</td><td>17%</td></tr><tr><td></td><td>$1,080</td><td></td><td></td></tr></table>
<table><tr><td>(in millions)</td><td>Cardiovascular</td><td>Rhythm Management</td><td>MedSurg</td><td>Total</td></tr><tr><td>Balance as of December 31, 2013</td><td>$3,252</td><td>$294</td><td>$2,147</td><td>$5,693</td></tr><tr><td>Purchase price adjustments</td><td>-2</td><td>-4</td><td>-2</td><td>-8</td></tr><tr><td>Goodwill acquired</td><td>169</td><td>—</td><td>44</td><td>213</td></tr><tr><td>Other changes in carrying amount*</td><td>7</td><td>$—</td><td>-7</td><td>—</td></tr><tr><td>Balance as of December 31, 2014</td><td>$3,426</td><td>$290</td><td>$2,182</td><td>$5,898</td></tr><tr><td>Purchase price adjustments</td><td>2</td><td>2</td><td>-2</td><td>2</td></tr><tr><td>Goodwill acquired</td><td>23</td><td>—</td><td>550</td><td>573</td></tr><tr><td>Balance as of December 31, 2015</td><td>$3,451</td><td>$292</td><td>$2,730</td><td>$6,473</td></tr></table>

Question: How many element exceed the average of Purchase price adjustments in 2013 for Cardiovascular ?